Higher dose firmonertinib for stable EGFR lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a higher dose of Firmonertinib (160 mg) can improve outcomes in patients whose advanced lung cancer has stayed stable after 8 weeks on the standard 80 mg dose. It's designed for people with a specific EGFR gene mutation who haven't had any prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years
- Able to perform daily activities with little to no help (ECOG 0-1)
- Advanced non-squamous lung cancer with an EGFR mutation (exon 19 deletion or L858R)
- No previous treatment for advanced disease (some may have had earlier treatments for early-stage cancer)
- Disease stable after 8 weeks of Firmonertinib 80 mg daily
- No major heart, lung, or other health problems that would interfere with treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted cancer drug called firmonertinib for early-stage lung adenocarcinoma that can be surgically removed. The drug targets a specific genetic mutation (EGFR) in the cancer cells and is given before and after surgery to help prevent the cancer from returning.
This trial tests a new targeted therapy called Firmonertinib for people with advanced EGFR-mutated non-small cell lung cancer. It uses a special blood test (liquid biopsy) to guide treatment and adjust it over time, aiming to make the therapy more personalized.
This trial tests a new drug, firmonertinib, against other EGFR inhibitors as a first treatment for advanced lung cancer that has specific rare EGFR mutations (PACC mutations). It is for people who haven't had other treatments for their advanced cancer.
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
This trial tests if a higher dose of furmonertinib can help people with a specific type of lung cancer (NSCLC) that has slowly gotten worse while taking osimertinib. It's for those whose cancer has an EGFR mutation and hasn't spread quickly.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.